Chronic Bronchitis News and Research

RSS

Relighting cigarettes related to economic factors, researchers find

In what is believed to be a first of its kind study, a research member at The Cancer Institute of New Jersey and colleagues have found that an accelerating trend of smokers relighting cigarettes is related to economic factors, and the practice has implications for tobacco dependence treatment and policy.

19 Mar 2013

Chronic obstructive pulmonary disease (COPD) inflammatory subtypes: an interview with Dr Vanessa McDonald, University of Newcastle, Australia

COPD is defined as a preventable and treatable disease associated with significant extrapulmonary consequences that may contribute to severity. The pulmonary component of COPD is characterised by airflow limitation that is not fully reversible. The airflow limitation is usually progressive with an abnormal inflammatory response of the lungs to noxious particles (GOLD Strategy Document). Airflow obstruction in COPD is not highly variable and largely irreversible.

8 Mar 2013

FDA approves Lupin Pharmaceuticals' SUPRAX for Oral Suspension

Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received approval for SUPRAX (Cefixime) for Oral Suspension, 500 mg/5mL from the United States Food and Drugs Administration (FDA).

23 Feb 2013

Bronchiectasis finding reveals COPD patients at mortality risk

Bronchiectasis is independently associated with mortality risk among patients with moderate-to-severe chronic obstructive pulmonary disease, Spanish research shows.

12 Feb 2013

Older adults with COPD more frequently use benzodiazepines

A popular class of drugs commonly used to treat sleep and mood symptoms continues to be frequently prescribed despite being known to have potentially life-threatening side effects.

9 Feb 2013

COPD underdiagnosed in Chinese lung cancer patients

Chronic obstructive pulmonary disease is underdiagnosed and undertreated among lung cancer patients in China, study results show.

4 Feb 2013

Almirall, Forest Laboratories' Tudorza Pressair now available in the U.S. pharmacies

Forest Laboratories, Inc. and Almirall, S.A. announced today that Tudorza Pressair (aclidinium bromide inhalation powder) 400mcg is now available in pharmacies throughout the United States.

11 Dec 2012

BRFSS survey offers state-level rates of COPD prevalence

The age-adjusted prevalence of chronic obstructive pulmonary disease (COPD) varies considerably within the United States, from less than 4 percent of the population in Washington and Minnesota to more than 9 percent in Alabama and Kentucky.

22 Nov 2012

MRC funds largest ever study of genetics relating to lung disease

Researchers from the Universities of Nottingham and Leicester are leading the largest ever study of the genetics relating to lung disease.

15 Nov 2012

X-ray technology improves early detection of pulmonary disease

Chronic obstructive pulmonary disease (COPD) is considered the fourth most common cause of death in the United States. Usually the precursor to this life-threatening lung disease is a chronic bronchitis. Partially destroyed alveoli and an over-inflation of the lungs, known as emphysema, are serious side effects. However, the subtle differences in the tissue are barely discernable in standard X-ray images.

23 Oct 2012

Alcohol consumption, college education may increase risk of COPD

College education and alcohol consumption may be linked to risk for chronic obstructive pulmonary disease (COPD). Researchers from Kaiser Permanente Medical Group in Oakland, California, followed 126,019 people who supplied baseline data from 1978 - 1985 through 2008 with analyses of hospitalizations attributed to COPD (emphysema, chronic bronchitis, or chronic airway obstruction).

22 Oct 2012

Empire BlueCross BlueShield introduces Medicare Advantage plans in New York City

Empire BlueCross BlueShield is introducing a number of Medicare Advantage (MA) plans in New York City that include access to the acclaimed CareMore health delivery system, which helps members maintain their health.

15 Oct 2012

Japanese MHLW approves Sosei’s Seebri inhalation capsules to treat COPD

Sosei Group Corporation confirms the information released today by Novartis that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Seebri (glycopyrronium bromide) Inhalation Capsules 50 mcg administered through the Breezhaler device, as a once-daily, long-term, inhaled maintenance bronchodilator treatment for the relief of various symptoms due to airway obstructive disease in chronic obstructive pulmonary disease.

28 Sep 2012

Patients with chronic obstructive pulmonary disease experience poor sleep quality

Patients with chronic obstructive pulmonary disease (COPD) experience poorer sleep quality than people of a similar age without COPD, according to research published in the journal Respirology.

21 Sep 2012

CT shows promise in predicting COPD exacerbation risk

Measurement of the pulmonary artery-to-aorta ratio can predict the risk for exacerbations in patients with chronic obstructive pulmonary disease, particularly those that require hospitalization, say the authors of a US study.

11 Sep 2012

Potential new COPD drug

A study led by researchers at Boston University School of Medicine (BUSM) has shown that a compound used in some skin creams may halt the progression of emphysema and reverse some of the damage caused by the disease. When the compound Gly-His-Lys (GHK) was applied to lung cells from patients with emphysema, normal gene activity in altered cells was restored and damaged aspects of cellular function were repaired.

1 Sep 2012